Principal Financial Group Inc. Has $9.01 Million Stake in LivaNova PLC (NASDAQ:LIVN)

Principal Financial Group Inc. lowered its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 19.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 171,402 shares of the company's stock after selling 41,335 shares during the quarter. Principal Financial Group Inc. owned approximately 0.32% of LivaNova worth $9,005,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Primecap Management Co. CA grew its holdings in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company's stock valued at $327,889,000 after purchasing an additional 44,049 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of LivaNova by 3.5% during the first quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company's stock valued at $102,537,000 after acquiring an additional 62,480 shares during the last quarter. Point72 Asset Management L.P. lifted its position in LivaNova by 204.3% during the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company's stock worth $70,479,000 after buying an additional 863,157 shares during the period. Magnetar Financial LLC lifted its position in LivaNova by 8.1% during the second quarter. Magnetar Financial LLC now owns 814,452 shares of the company's stock worth $44,648,000 after buying an additional 61,114 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in LivaNova by 3.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock worth $41,889,000 after buying an additional 25,277 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Trading Down 0.6 %

Shares of LIVN stock traded down $0.31 during trading hours on Tuesday, reaching $52.22. The company had a trading volume of 110,838 shares, compared to its average volume of 615,647. The firm has a market cap of $2.84 billion, a price-to-earnings ratio of 125.07 and a beta of 1.01. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a 50 day moving average of $51.88 and a 200 day moving average of $52.79.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on LIVN shares. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. Mizuho dropped their target price on LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, October 31st. The Goldman Sachs Group started coverage on LivaNova in a research note on Friday, October 4th. They set a "buy" rating and a $65.00 price objective for the company. StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Finally, Stifel Nicolaus raised their price objective on LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, LivaNova currently has an average rating of "Buy" and a consensus price target of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.